Work

Pos0260 Once-monthly Sel-212 Demonstrates Efficacy and Safety for up to 6-months in Gout Refractory to Conventional Therapy: Combined Data From the Dissolve I & Ii Phase 3, Double-blind, Placebo-controlled Clinical Trials

Year: 2024

Type: conference-abstract

Source: Annals of the Rheumatic Diseases

DOI: 10.1136/annrheumdis-2024-eular.2832

Authors: H.S.B. Baraf, P. Khanna, A. Patel, A. Singhal, J. Sobierska, H. Santin-Janin, R. Azeem, W. Dehaan, P. Traber, A. Kivitz

Institutions: George Washington University, University of Michigan, Altoona Center for Clinical Research

Language: English

Topic: Gout, Hyperuricemia, Uric Acid

Subfield: Nephrology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4399481403

Cites:

Cited by: 3

Related to: 10